Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
According to statistics, as of mid-2025, there were approximately 277 obesity drugs in development globally, but the vast majority were still in preclinical or Phase I stages
Considering promising preclinical data (Table 1) and clinical pilot study results in the GLP-2 analog, teduglutide may have potential to become a new therapeutic option in IBD treatment, showing higher response and remission rates in comparison to placebo (Buchman et al
However, patients on these medications exhibited profound weight-loss, prompting Novo, Lilly, Amgen, and other pharma companies to investigate how these drugs can be used specifically to treat obesity
However, patients who built strong protein-based nutrition habits, maintained muscle mass through resistance exercise, and followed a physician-guided tapering plan maintain significantly more of their weight loss
